CarMa Global Enterprise is a platform for founders, scientists, innovators, and thinkers advancing life sciences, artificial intelligence, and the technologies redefining how humanity evolves, builds, and sustains itself. We connect their vision to capital with patience and conviction — because the ideas that will shape humanity's future should not be gatekept by geography, privilege, or the absence of the right introduction.
CarMa operates across four integrated verticals — each purpose-built for a distinct phase of the capital and innovation lifecycle.
Our strategic advisory arm — working with founders and innovators we back, and select companies across our broader network, to navigate the full capital journey from early fundraising to Series C across MENA and APAC.
Learn MoreOur in-house investment vehicle deploying LP capital into the founders redefining the frontier across life sciences, artificial intelligence, and deep technology. Fund I closed at $60M. Fund II in formation at $150M.
Explore FundOur dedicated arm for the next generation of artificial intelligence — backing Health-AI, Physical AI, and Enterprise AI at pre-seed and seed stage, before the world is ready to name the category.
Explore IntelligenceWhere ideas are born before the market knows to ask for them. Our venture studio will develop in-house IP, incubate external founders, and build companies from conviction rather than convention.
Coming 2027"The next era of frontier innovation will not be defined by where the science originates — it will be defined by who gets access to the capital that scales it. We believe Eastern capital is the force that makes that access global."
Four principles guide every decision we make — from the first conversation with a founder to the final close of a round.
Every decision at CarMa begins with the science. Our team brings medical and scientific backgrounds to every evaluation — not as a credential, but as a lens. We do not fund stories. We fund substance and vision.
Consensus is a lagging indicator. We move early — when the science is hard, the narrative is unformed, and the opportunity is invisible to those who wait for permission.
Capital has geography. Eastern capital carries a different kind of reach. When it enters the equation, frontier innovation stops being a regional story and becomes a global one.
We do not move on quarterly cycles. Patient capital is smart capital. And the impact on the other side of these bets is not a return multiple. It is a change in how humanity lives.